Story perspectives

South Africa Trials EDP for Enhanced HIV Antibody Responses

9/3/2025

Summary

Story summary

A phase 1 trial in Durban, South Africa, involved 57 HIV-negative participants to assess recombinant human hyaluronidase (EDP) effects on bNAbs.
Participants were divided into four groups, receiving either EDP or non-EDP formulations.
Plasma concentration data contributed to a population pharmacokinetic model for dose-normalized comparisons.
The study evaluated anti-drug antibodies (ADAs) using multiple administration strategies for bNAbs.
Each subgroup had five participants, with a 4:1 active treatment to placebo ratio.

1 of 1

Story summary

A phase 1 trial in Durban, South Africa, involved 57 HIV-negative participants to assess recombinant human hyaluronidase (EDP) effects on bNAbs.
Participants were divided into four groups, receiving either EDP or non-EDP formulations.
Plasma concentration data contributed to a population pharmacokinetic model for dose-normalized comparisons.
The study evaluated anti-drug antibodies (ADAs) using multiple administration strategies for bNAbs.
Each subgroup had five participants, with a 4:1 active treatment to placebo ratio.